ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "3573ae2e-8d1b-4ffd-9d3d-57f2052cb36b"}, "_deposit": {"created_by": 14, "id": "2174", "owners": [14], "pid": {"revision_id": 0, "type": "depid", "value": "2174"}, "status": "published"}, "_oai": {"id": "oai:dmu.repo.nii.ac.jp:00002174", "sets": ["178"]}, "author_link": ["10204", "10206", "6301", "715", "10203", "10205", "6300"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-03-25", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "27", "bibliographicPageStart": "17", "bibliographicVolumeNumber": "46", "bibliographic_titles": [{"bibliographic_title": "Dokkyo Journal of Medical Sciences"}]}]}, "item_10001_description_34": {"attribute_name": "要旨", "attribute_value_mlt": [{"subitem_description": "  More than few patients on maintenance hemodialysis present with hyperuricemia, and the control of serum uric acid level is an important issue in the long-term management. In addition to allopurinol, febuxostat can be used as a xanthine oxidase inhibitor in hemodialysis patients. In this study, the clinical effects of febuxostat were compared with allopurinol in chronic hemodialysis patients. Eligible hemodialysis patients taking allopurinol were randomly assigned to take 100 mg allopurinol(n=26)or 20 mg febuxostat(n=23)for 12 weeks. Serum uric acid was markedly lowered in the febuxostat group(0-week 6.7 mg/dL, 12-week 4.3 mg/dL, p<0.001)as compared with the allopurinol group(0-week 6.0 mg/dL, 12-week 5.8 mg/dL)and systolic blood pressure was lowered by 5 mmHg(p=0.036)at 4-week in the febuxostat group while blood pressure was not significantly changed in the allopurinol group throughout the study period. In addition, the dose of erythropoiesis stimulating agent was reduced(0-week 22.2 μg/wk, 12-week, 17.1 μg/wk, p=0.012)and serum phosphate level was lowered(0-week 5.9 mg/dL, 12-week 5.1 mg/dL, p=0.027)in the febuxostat group but not in the allopurinol group. It is concluded that febuxostat is more effective in lowering serum uric acid than allopurinol in hemodialysis patients. In addition, it is suggested that febuxostat has an advantage in the management of renal anemia and hyperphosphatemia as well as hyperuricemia.", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "獨協医学会"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03855023", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_text_24": {"attribute_name": "著者所属", "attribute_value_mlt": [{"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}]}, "item_10001_text_33": {"attribute_name": "記事種別", "attribute_value_mlt": [{"subitem_text_value": "Original"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nagase, Akihiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10203", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishimitsu, Toshihiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "715", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furuichi, Masahito", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6300", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Onoda, Shou", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10204", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohira, Takehiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10205", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murayama, Yoshiki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6301", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tojo Akihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10206", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-04-25"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "DJMS-46-1-4.pdf", "filesize": [{"value": "307.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 307500.0, "url": {"label": "DJMS-46-1-Nagase-本文", "url": "https://dmu.repo.nii.ac.jp/record/2174/files/DJMS-46-1-4.pdf"}, "version_id": "5ec1d90f-9a89-452f-9605-b4a6841b29a6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "uric acid", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hyperuricemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hemodialysis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "xanthine oxidase inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "febuxostat", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients"}]}, "item_type_id": "10001", "owner": "14", "path": ["178"], "permalink_uri": "https://dmu.repo.nii.ac.jp/records/2174", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-04-25"}, "publish_date": "2019-04-25", "publish_status": "0", "recid": "2174", "relation": {}, "relation_version_is_last": true, "title": ["Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients"], "weko_shared_id": -1}
  1. Dokkyo Journal of Medical Sciences
  2. 46(1) 2019

Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients

https://dmu.repo.nii.ac.jp/records/2174
https://dmu.repo.nii.ac.jp/records/2174
da6565ae-e0db-4e87-a283-91de5e37c1a8
名前 / ファイル ライセンス アクション
DJMS-46-1-4.pdf DJMS-46-1-Nagase-本文 (307.5 kB)
Item type 学術雑誌論文 / Journal Article(1)
タイトル
タイトル Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients
言語
言語 eng
キーワード
主題 uric acid
キーワード
主題 hyperuricemia
キーワード
主題 hemodialysis
キーワード
主題 xanthine oxidase inhibitor
キーワード
主題 febuxostat
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Nagase, Akihiko

× Nagase, Akihiko

WEKO 10203

en Nagase, Akihiko

Search repository
Ishimitsu, Toshihiko

× Ishimitsu, Toshihiko

WEKO 715

en Ishimitsu, Toshihiko

Search repository
Furuichi, Masahito

× Furuichi, Masahito

WEKO 6300

en Furuichi, Masahito

Search repository
Onoda, Shou

× Onoda, Shou

WEKO 10204

en Onoda, Shou

Search repository
Ohira, Takehiro

× Ohira, Takehiro

WEKO 10205

en Ohira, Takehiro

Search repository
Murayama, Yoshiki

× Murayama, Yoshiki

WEKO 6301

en Murayama, Yoshiki

Search repository
Tojo Akihiro

× Tojo Akihiro

WEKO 10206

en Tojo Akihiro

Search repository
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
書誌情報 Dokkyo Journal of Medical Sciences

巻 46, 号 1, p. 17-27, 発行日 2019-03-25
要旨
内容記述タイプ Other
内容記述 More than few patients on maintenance hemodialysis present with hyperuricemia, and the control of serum uric acid level is an important issue in the long-term management. In addition to allopurinol, febuxostat can be used as a xanthine oxidase inhibitor in hemodialysis patients. In this study, the clinical effects of febuxostat were compared with allopurinol in chronic hemodialysis patients. Eligible hemodialysis patients taking allopurinol were randomly assigned to take 100 mg allopurinol(n=26)or 20 mg febuxostat(n=23)for 12 weeks. Serum uric acid was markedly lowered in the febuxostat group(0-week 6.7 mg/dL, 12-week 4.3 mg/dL, p<0.001)as compared with the allopurinol group(0-week 6.0 mg/dL, 12-week 5.8 mg/dL)and systolic blood pressure was lowered by 5 mmHg(p=0.036)at 4-week in the febuxostat group while blood pressure was not significantly changed in the allopurinol group throughout the study period. In addition, the dose of erythropoiesis stimulating agent was reduced(0-week 22.2 μg/wk, 12-week, 17.1 μg/wk, p=0.012)and serum phosphate level was lowered(0-week 5.9 mg/dL, 12-week 5.1 mg/dL, p=0.027)in the febuxostat group but not in the allopurinol group. It is concluded that febuxostat is more effective in lowering serum uric acid than allopurinol in hemodialysis patients. In addition, it is suggested that febuxostat has an advantage in the management of renal anemia and hyperphosphatemia as well as hyperuricemia.
記事種別
Original
出版者
出版者 獨協医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 03855023
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 15:35:00.786023
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3